



## Restrictions on Transactions in Anthera Pharmaceuticals, Inc. (ANTH) on Cboe Options Exchange

**Reference ID:** C2018062701

### **Overview**

Effective June 28, 2018, Anthera Pharmaceuticals, Inc. (ANTH) was delisted from the NASDAQ. Therefore, trading in ANTH options will be subject to restrictions pursuant to Cboe Options Rule 5.4. Trading in the overlying option class will only occur if a market develops in an over-the-counter market for ANTH. In addition, transactions in contravention of this restriction may be subject to nullification pursuant to Cboe Options Rule 6.25.

There are no restrictions in place with respect to the exercise of ANTH options.

### **Additional Information**

Please contact the Cboe Operations Support Center (“OSC”) or Regulatory Interps with any questions.

#### **Cboe Operations Support Center**

312.786.7351

[marketservices@cboe.com](mailto:marketservices@cboe.com)

#### **Regulatory Interps.**

312.786.8141

[reginterps@cboe.com](mailto:reginterps@cboe.com)